Vitamin D–VDR Signaling Across Thyroid Disorders: A Systematic Review of Molecular Mechanisms, Autoimmunity, Genetic Susceptibility, Experimental Evidence and Therapeutic Translation
7 affiliations
- 1Department of Pharmacology, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates
- 2A. J. Hospital and Research Centre, A. J. Institute of Hospital Management, Mangalore 575004, India
- 3Department of Pathological Sciences, College of Medicine, Ajman University, Ajman 346, United Arab Emirates
- 4Faculty of Medicine, Manipal University College Malaysia, Melaka 75150, Malaysia
- 5Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal 576104, India
- 6RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates
- 7Department of Pharmacology, Alva’s Institute of Medical Science and Research Centre, Moodbidri 574227, India
Abstract
Vitamin D–Vitamin D receptor (VDR) signaling extends beyond calcium-phosphate homeostasis and regulates immune tolerance, inflammation, cellular differentiation, oxidative stress, and endocrine physiology. This systematic review evaluated the relationship between vitamin D–VDR signaling and thyroid disorders, including hypothyroidism, hyperthyroidism, Hashimoto’s thyroiditis, Graves’ disease, thyroid autoimmunity, genetic susceptibility, experimental mechanisms, and therapeutic implications. This study was conducted and reported in accordance with the PRISMA 2020 statement. PubMed/MEDLINE and Scopus were searched for studies published from January 2005 through June 2026, supplemented by backward and forward citation screening of relevant studies and reviews. Eligible evidence included human observational and interventional studies, genetic investigations, and relevant animal and in vitro studies addressing vitamin D status, vitamin D exposure or supplementation, VDR variation, vitamin D metabolism, or vitamin D–VDR mechanisms in relation to thyroid function, thyroid disease, thyroid autoantibodies, or related biological outcomes. A total of 13,623 records were identified, of which 11,730 unique records underwent title and abstract screening, 449 reports were assessed at the full-text stage, and 118 primary studies were included in the final synthesis. Because of substantial heterogeneity in populations, study designs, vitamin D exposures, outcomes, genetic backgrounds, and experimental models, findings were synthesized narratively rather than by quantitative meta-analysis. Lower circulating 25-hydroxyvitamin D [25(OH)D] concentrations were frequently associated with thyroid disease, particularly autoimmune phenotypes, and increased thyroid peroxidase and thyroglobulin antibodies in Hashimoto’s thyroiditis. Interventional evidence suggests that vitamin D supplementation may reduce thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) concentrations in some patients with autoimmune thyroid disease. However, these laboratory changes represent immunological surrogate outcomes and should not be interpreted as evidence of restored thyroid function, prevention of progression to overt hypothyroidism, reduced dependence on thyroid hormone replacement, or sustained clinical remission. Randomized evidence does not establish a general preventive effect of vitamin D supplementation on incident hypothyroidism. Associations between VDR polymorphisms, including FokI/rs2228570, rs1544410, rs731236, and rs7975232, and thyroid autoimmunity were inconsistent across populations. Experimental evidence implicates immune regulation, Th17/Treg balance, inflammatory signaling, vitamin D metabolism, and calcium-phosphate homeostasis. The evidence was limited by substantial clinical, methodological, and biological heterogeneity, frequent reliance on observational studies, population-specific genetic findings, and differences between experimental models and human thyroid physiology. Overall, vitamin D–VDR signaling represents a biologically plausible modifier of thyroid disease, but current evidence does not establish universal causality or therapeutic efficacy.
Related
- Photothrombotic Ischemic Stroke in Rats: A Systematic Review of Experimental Parameters and Therapeutic Applications in Neuroprotection, Neuromodulation, and Post-Stroke Recovery
- Bidirectional association between thyroid autoimmunity/thyroglobulin antibody and diminished ovarian reserve: a systematic review and meta-analysis of observational studies
- Antibody-Related Mechanisms in Ocular Diseases: Autoimmunity, Malignancy, and Therapeutic Targeting.
- TACC3-driven translation reprogramming dictates susceptibility or tolerance to mitotic stress
- Circulating Biomarkers with Artificial Intelligence for Clinical Risk Assessment and Therapeutic Monitoring: Evidence, Limitations, and Translation
BibTeX
@article{satyam2026vitamin,
title = {{Vitamin D–VDR Signaling Across Thyroid Disorders: A Systematic Review of Molecular Mechanisms, Autoimmunity, Genetic Susceptibility, Experimental Evidence and Therapeutic Translation}},
author = {Shakta Mani Satyam and Murk Jai Pal Paryani and Ilmia Shameer and Shams Al-dawoodi and Ebrahim Safaii and Rashmi Kumari and Abdul Rehman and Hussein Saleh and Prakashchandra Shetty and Sainath Prabhakar and Bhoomendra Bhongade and Laxminarayana Kurady Bairy and Afnan Afroz and Manasvi Udaya Kumar and Karthik Nair and Anuradha Asokan Nair},
journal = {Biomolecules},
year = {2026},
month = oct,
doi = {10.3390/biom16101532},
url = {https://www.mdpi.com/2218-273X/16/10/1532},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Vitamin D–VDR Signaling Across Thyroid Disorders: A Systematic Review of Molecular Mechanisms, Autoimmunity, Genetic Susceptibility, Experimental Evidence and Therapeutic Translation
AU - Shakta Mani Satyam
AU - Murk Jai Pal Paryani
AU - Ilmia Shameer
AU - Shams Al-dawoodi
AU - Ebrahim Safaii
AU - Rashmi Kumari
AU - Abdul Rehman
AU - Hussein Saleh
AU - Prakashchandra Shetty
AU - Sainath Prabhakar
AU - Bhoomendra Bhongade
AU - Laxminarayana Kurady Bairy
AU - Afnan Afroz
AU - Manasvi Udaya Kumar
AU - Karthik Nair
AU - Anuradha Asokan Nair
PY - 2026
DA - 2026/10/01
JO - Biomolecules
DO - 10.3390/biom16101532
UR - https://www.mdpi.com/2218-273X/16/10/1532
AB - Vitamin D–Vitamin D receptor (VDR) signaling extends beyond calcium-phosphate homeostasis and regulates immune tolerance, inflammation, cellular differentiation, oxidative stress, and endocrine physiology. This systematic review evaluated the relationship between vitamin D–VDR signaling and thyroid disorders, including hypothyroidism, hyperthyroidism, Hashimoto’s thyroiditis, Graves’ disease, thyroid autoimmunity, genetic susceptibility, experimental mechanisms, and therapeutic implications. This study was conducted and reported in accordance with the PRISMA 2020 statement. PubMed/MEDLINE and Scopus were searched for studies published from January 2005 through June 2026, supplemented by backward and forward citation screening of relevant studies and reviews. Eligible evidence included human observational and interventional studies, genetic investigations, and relevant animal and in vitro studies addressing vitamin D status, vitamin D exposure or supplementation, VDR variation, vitamin D metabolism, or vitamin D–VDR mechanisms in relation to thyroid function, thyroid disease, thyroid autoantibodies, or related biological outcomes. A total of 13,623 records were identified, of which 11,730 unique records underwent title and abstract screening, 449 reports were assessed at the full-text stage, and 118 primary studies were included in the final synthesis. Because of substantial heterogeneity in populations, study designs, vitamin D exposures, outcomes, genetic backgrounds, and experimental models, findings were synthesized narratively rather than by quantitative meta-analysis. Lower circulating 25-hydroxyvitamin D [25(OH)D] concentrations were frequently associated with thyroid disease, particularly autoimmune phenotypes, and increased thyroid peroxidase and thyroglobulin antibodies in Hashimoto’s thyroiditis. Interventional evidence suggests that vitamin D supplementation may reduce thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) concentrations in some patients with autoimmune thyroid disease. However, these laboratory changes represent immunological surrogate outcomes and should not be interpreted as evidence of restored thyroid function, prevention of progression to overt hypothyroidism, reduced dependence on thyroid hormone replacement, or sustained clinical remission. Randomized evidence does not establish a general preventive effect of vitamin D supplementation on incident hypothyroidism. Associations between VDR polymorphisms, including FokI/rs2228570, rs1544410, rs731236, and rs7975232, and thyroid autoimmunity were inconsistent across populations. Experimental evidence implicates immune regulation, Th17/Treg balance, inflammatory signaling, vitamin D metabolism, and calcium-phosphate homeostasis. The evidence was limited by substantial clinical, methodological, and biological heterogeneity, frequent reliance on observational studies, population-specific genetic findings, and differences between experimental models and human thyroid physiology. Overall, vitamin D–VDR signaling represents a biologically plausible modifier of thyroid disease, but current evidence does not establish universal causality or therapeutic efficacy.
SN - 2218-273X
ER -